Hassan Fred
- SEC CIK
- 0001110744
No open-market purchases or sales filed in the past year.
Current role at each company
- BBIO BridgeBio Pharma, Inc.Directoras of Jun 24, 2026
- PGEN Precigen, Inc.Directoras of Mar 16, 2026
- COCP Cocrystal Pharma, Inc.Directoras of Jan 13, 2026
- EYPT EyePoint, Inc.Directoras of Jan 6, 2026
- RXDX Prometheus Biosciences, Inc.Directoras of Jun 16, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Hassan Fred as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
PGEN Precigen, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2023 (view filing) | Aug 14 | 2 days | Hassan FredDirector | PPurchase | +570.3K | $1.75 | +$998.1K | +184.8%878.9K after |
BBIO BridgeBio Pharma, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2022 (view filing) | Dec 29, 2021 | 5 days | Hassan FredDirector | PPurchase | +19.3K | $14.17 | +$273.5K | New position19.3K after |